Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Bright Minds Biosciences Inc. (DRUG) had Normalized Income after Taxes of $-7.62M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-7.62M |
|
-- |
|
-- |
|
$11.17M |
|
$-11.17M |
|
$3.54M |
|
$-7.62M |
|
$-7.62M |
|
$-7.62M |
|
$-7.62M |
|
$-7.62M |
|
|
Normalized Income after Taxes |
$-7.62M |
$-11.17M |
|
$-11.15M |
|
9.59M |
|
9.59M |
|
$-0.79 |
|
$-0.79 |
|
| Balance Sheet Financials | |
$227.63M |
|
-- |
|
$0.05M |
|
$227.68M |
|
$2.79M |
|
-- |
|
-- |
|
$2.79M |
|
$224.89M |
|
$224.89M |
|
$224.89M |
|
9.81M |
|
| Cash Flow Statement Financials | |
$-10.98M |
|
-- |
|
$176.29M |
|
$60.43M |
|
$225.73M |
|
$165.30M |
|
$1.82M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
81.48 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-10.98M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-3.39% |
|
-3.39% |
|
-3.35% |
|
-3.39% |
|
$22.92 |
|
$-1.14 |
|
$-1.14 |
|